Search hospitals > Iowa > Des Moines
Medical Oncology and Hematology Associates-Des Moines
Claim this profileDes Moines, Iowa 50309
Global Leader in Skin Cancer
Global Leader in Relapse
Conducts research for Breast Cancer
Conducts research for Stomach Cancer
Conducts research for Ovarian Cancer
323 reported clinical trials
2 medical researchers
Summary
Medical Oncology and Hematology Associates-Des Moines is a medical facility located in Des Moines, Iowa. This center is recognized for care of Skin Cancer, Relapse, Breast Cancer, Stomach Cancer, Ovarian Cancer and other specialties. Medical Oncology and Hematology Associates-Des Moines is involved with conducting 323 clinical trials across 452 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Relapse
Global LeaderStage IV
Stage III
Stage I
Top PIs
Joshua LukenbillMedical Oncology and Hematology Associates-Des Moines2 years of reported clinical research
Expert in Skin Cancer
Expert in Cancer
140 reported clinical trials
215 drugs studied
Robert J. BehrensIowa Methodist Medical Center4 years of reported clinical research
Expert in Skin Cancer
Studies Breast Cancer
43 reported clinical trials
97 drugs studied
Clinical Trials running at Medical Oncology and Hematology Associates-Des Moines
Skin Cancer
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Prostate Cancer
Bladder Cancer
Squamous Cell Carcinoma
Breast cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Focused Radiation vs Systemic Therapy
for Kidney Cancer
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get for metastatic kidney cancer which includes systemic therapy such as immunotherapy (given through the veins) and/or small molecular inhibitor (tablets taken by mouth). Radiotherapy uses high energy x-rays to kill cancer cells and shrink tumors. SAbR uses special equipment to position a patient and deliver radiation to tumors with high precision. Giving SAbR prior to systemic therapy may kill more tumor cells than the usual approach, which is systemic therapy alone.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Medical Oncology and Hematology Associates-Des Moines?
Medical Oncology and Hematology Associates-Des Moines is a medical facility located in Des Moines, Iowa. This center is recognized for care of Skin Cancer, Relapse, Breast Cancer, Stomach Cancer, Ovarian Cancer and other specialties. Medical Oncology and Hematology Associates-Des Moines is involved with conducting 323 clinical trials across 452 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.
Where is Medical Oncology and Hematology Associates-Des Moines located?
Medical Oncology and Hematology Associates-Des Moines is situated at 1221 Pleasant St, Suite 100, Des Moines, IA 50309, conveniently located near the center of Des Moines.
Who should I call to ask about financial aid or insurance network?
At Medical Oncology and Hematology Associates, patients have access to financial counselors during their initial visits and whenever they have inquiries about their account or insurance coverage. These counselors are insurance experts ready to answer questions and confirm that a coverage plan is in place before treatment starts. They can also provide information on patient assistance programs and payment options.
What insurance does Medical Oncology and Hematology Associates-Des Moines accept?
Medical Oncology & Hematology Associates in Des Moines, IA, accepts all insurance plans. Patients must have an updated insurance card on file. Copayments, deductibles, and coinsurance are due at each visit, with any charges not covered by insurance being the responsibility of the patient or guarantor.
What awards or recognition has Medical Oncology and Hematology Associates-Des Moines received?
Medical Oncology and Hematology Associates-Des Moines, located in Des Moines, Iowa, is celebrated for its contributions to cancer research and patient care. The hospital has been actively involved in clinical trials with prestigious research groups, including the Mayo Clinic Cancer Center’s North Central Cancer Treatment Group, Eastern Cooperative Oncology Group, Southwest Oncology Group, and National Surgical Adjuvant Breast and Bowel Project. It has also been at the forefront of adjuvant therapies for colon and rectal cancers for over twenty years and registered the first patient for a clinical trial under Vice President Joe Biden’s Cancer Moonshot initiative.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.